BioNTech SE Share Price Xetra
Stocks
US09075V1026
Biotechnology & Medical Research
| Market Cap | 20.23B 23.07B 18.64B 17.45B 32.73B 2,176B 33.41B 224B 86.71B 1,075B 86.62B 84.73B 3,729B | P/E 2026 * |
-18.2x | P/E 2027 * | -17.9x |
|---|---|---|---|---|---|
| Enterprise Value | 9.37B 10.69B 8.64B 8.09B 15.17B 1,009B 15.48B 104B 40.19B 498B 40.14B 39.27B 1,728B | EV / Sales 2026 * |
4.33x | EV / Sales 2027 * | 4.91x |
| Free-Float |
96.06% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: BioNTech SE
| 1 day | +2.27% |
| Manager | Title | Age | Since |
|---|---|---|---|
Özlem Türeci
CTO | Chief Tech/Sci/R&D Officer | 59 | 31/12/2017 |
Ugur Sahin
CEO | Chief Executive Officer | 60 | 01/06/2008 |
| Director of Finance/CFO | - | 30/06/2025 |
| Director | Title | Age | Since |
|---|---|---|---|
Helmut Jeggle
CHM | Chairman | 55 | 01/06/2008 |
| Director/Board Member | 69 | 01/06/2008 | |
| Director/Board Member | 65 | 31/12/2017 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +2.27% | +2.41% | - | - | 23.07B | |
| +0.33% | +1.37% | +63.66% | +123.67% | 55.63B | |
| +0.82% | +15.05% | +79.52% | +88.67% | 52.25B | |
| -1.04% | +7.91% | +3.91% | +413.05% | 22.41B | |
| +6.90% | +14.90% | +37.70% | -1.75% | 17.32B | |
| -1.10% | +4.00% | +29.97% | -32.75% | 15.94B | |
| +2.89% | +5.51% | +25.42% | +188.41% | 13.77B | |
| -3.35% | +8.96% | +134.32% | +282.61% | 13.47B | |
| +6.32% | +13.25% | +35.82% | - | 12.43B | |
| -0.22% | +1.36% | +70.46% | +131.26% | 11.82B | |
| Average | +1.38% | +4.89% | +53.42% | +149.14% | 23.89B | |
| Weighted average by Cap. | +1.10% | +5.44% | +57.44% | +139.02% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 2.17B 2.47B 2B 1.87B 3.5B 233B 3.58B 24B 9.28B 115B 9.28B 9.07B 399B | 2.23B 2.54B 2.06B 1.92B 3.61B 240B 3.68B 24.71B 9.56B 119B 9.55B 9.34B 411B |
| Net income | -1.05B -1.2B -969M -907M -1.7B -113B -1.74B -11.64B -4.5B -55.88B -4.5B -4.4B -194B | -1.17B -1.33B -1.07B -1.01B -1.89B -125B -1.92B -12.91B -5B -61.96B -4.99B -4.88B -215B |
| Net Debt | -10.85B -12.38B -10B -9.37B -17.56B -1,168B -17.93B -120B -46.52B -577B -46.48B -45.46B -2,001B | -9.28B -10.58B -8.55B -8.01B -15.02B -998B -15.33B -103B -39.79B -493B -39.75B -38.88B -1,711B |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
